and do not use sell limits so MMs can seek them out.
Thanks again. It is odd why both ACHN and DVAX are being sold as though they have nothing of value to Big pharma.
Thanks for inform reply. Since Dynavax has also found Heplisav to work against HepC, what chance would you give it for making it to market before Sovaprevir?
while they develop momentum to 3-5 year highs. ty